EP Wealth Advisors LLC Makes New Investment in Hologic, Inc. (NASDAQ:HOLX)

EP Wealth Advisors LLC bought a new stake in Hologic, Inc. (NASDAQ:HOLX) during the 3rd quarter, HoldingsChannel reports. The fund bought 9,956 shares of the medical equipment provider’s stock, valued at approximately $811,000.

Other institutional investors have also recently made changes to their positions in the company. Cetera Investment Advisers raised its position in Hologic by 188.9% in the 1st quarter. Cetera Investment Advisers now owns 20,464 shares of the medical equipment provider’s stock worth $1,595,000 after purchasing an additional 13,380 shares during the period. Sequoia Financial Advisors LLC grew its stake in shares of Hologic by 2.3% during the second quarter. Sequoia Financial Advisors LLC now owns 7,215 shares of the medical equipment provider’s stock valued at $536,000 after buying an additional 165 shares during the last quarter. Wedmont Private Capital lifted its stake in shares of Hologic by 6.0% during the 2nd quarter. Wedmont Private Capital now owns 4,357 shares of the medical equipment provider’s stock worth $338,000 after acquiring an additional 247 shares during the last quarter. Wealth Enhancement Advisory Services LLC lifted its stake in shares of Hologic by 11.3% during the 2nd quarter. Wealth Enhancement Advisory Services LLC now owns 4,804 shares of the medical equipment provider’s stock worth $357,000 after acquiring an additional 487 shares during the last quarter. Finally, Trivant Custom Portfolio Group LLC purchased a new position in Hologic during the 2nd quarter valued at $549,000. Institutional investors own 94.73% of the company’s stock.

Hologic Price Performance

Shares of HOLX stock opened at $76.83 on Wednesday. The stock’s 50-day moving average is $79.62 and its 200 day moving average is $78.60. Hologic, Inc. has a 1-year low of $68.15 and a 1-year high of $84.67. The company has a debt-to-equity ratio of 0.49, a current ratio of 3.69 and a quick ratio of 3.03. The company has a market cap of $17.44 billion, a P/E ratio of 23.07, a PEG ratio of 2.37 and a beta of 0.96.

Hologic (NASDAQ:HOLX) last issued its quarterly earnings data on Monday, November 4th. The medical equipment provider reported $1.01 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $1.01. The firm had revenue of $987.90 million for the quarter, compared to the consensus estimate of $978.25 million. Hologic had a net margin of 19.59% and a return on equity of 19.79%. The company’s quarterly revenue was up 4.5% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.89 EPS. Research analysts predict that Hologic, Inc. will post 4.28 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, COO Essex D. Mitchell sold 24,856 shares of the firm’s stock in a transaction on Wednesday, December 4th. The stock was sold at an average price of $76.34, for a total value of $1,897,507.04. Following the completion of the sale, the chief operating officer now owns 27,957 shares of the company’s stock, valued at $2,134,237.38. This trade represents a 47.06 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Corporate insiders own 1.75% of the company’s stock.

Wall Street Analysts Forecast Growth

Several analysts have recently weighed in on HOLX shares. UBS Group lifted their target price on Hologic from $84.00 to $90.00 and gave the stock a “neutral” rating in a research report on Tuesday, November 5th. Royal Bank of Canada lifted their price objective on shares of Hologic from $86.00 to $89.00 and gave the company a “sector perform” rating in a report on Tuesday, November 5th. JPMorgan Chase & Co. raised their target price on shares of Hologic from $92.00 to $94.00 and gave the stock an “overweight” rating in a research report on Tuesday, November 5th. Jefferies Financial Group initiated coverage on Hologic in a report on Tuesday. They issued a “hold” rating and a $85.00 price target for the company. Finally, Mizuho reduced their price objective on Hologic from $90.00 to $87.00 and set an “outperform” rating on the stock in a report on Tuesday, November 5th. Five equities research analysts have rated the stock with a hold rating and nine have issued a buy rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $89.50.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.